3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
211
Neoplasm Metastasis
16
Neoplasms
9
Breast Neoplasms, Male
7
Breast Diseases
7
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Recurrence
2
Prostatic Neoplasms
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexuality
1
Sexual Dysfunctions, Psychological
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Primary Breast Cancer ER+ve
1
Interventions
Fulvestrant
6
Letrozole
4
exemestane
3
dalpiciclib
3
Trastuzumab
3
Docetaxel
3
Capecitabine
3
Anastrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
nirogacestat
1
margetuximab
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Tamoxifen
1
Rogaratinib
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Breast Cancer Metastatic
×
exemestane
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts
NCT03555877
2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2
Completed
56 enrolled
NCT02511639
2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3
Completed
110 enrolled